| Targretin oral (bexarotene oral) / ReXceptor |
NCT00003752: Bexarotene in Treating Patients With Metastatic Breast Cancer |
|
|
| Completed | 2 | 180 | US | bexarotene | Ligand Pharmaceuticals | Breast Cancer | | 03/03 | | |
NCT00030849: Bexarotene and Interferon Alfa in Treating Patients With Cutaneous T-Cell Lymphoma |
|
|
| Completed | 2 | | US | recombinant interferon alfa, bexarotene | Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI) | Lymphoma | 09/04 | 12/09 | | |
NCT00002212: A Study of Targretin Capsules in Patients With AIDS-Related Kaposi's Sarcoma |
|
|
| Completed | 2 | 27 | US | Bexarotene | Ligand Pharmaceuticals | Sarcoma, Kaposi, HIV Infections | | | | |
NCT00178841: Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL |
|
|
| Completed | 2 | 4 | US | Rosiglitazone and Bexarotene | Vanderbilt University | Cutaneous T-cell Lymphoma, Mycosis Fungoides, Sezary Syndrome | 03/07 | 03/07 | | |
GemBex, NCT00660231 / 2006-000591-33: Gemcitabine and Bexarotene in Treating Patients With Progressive or Refractory Stage IB, Stage II, Stage III, or Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma |
|
|
| Completed | 2 | 36 | Europe | bexarotene, Targretin, gemcitabine hydrochloride | University College, London | Lymphoma | 09/11 | 01/14 | | |
NCT00514293: Bexarotene, Tretinoin, and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer |
|
|
| Unknown status | 2 | 39 | US | bexarotene, capecitabine, carboplatin, cisplatin, docetaxel, tretinoin | Raghu Nandan, M.D., Inc | Lung Cancer | 12/11 | | | |
NCT00958074: Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma |
|
|
| Terminated | 2 | 11 | US | vorinostat, L-001079038, SAHA, suberoylanilide hydroxamic acid, Zolinza, flow cytometry, laboratory biomarker analysis | University of Washington, National Cancer Institute (NCI) | Cutaneous T-cell Lymphoma Stage I, Cutaneous T-cell Lymphoma Stage II, Cutaneous T-cell Lymphoma Stage III, Cutaneous T-cell Lymphoma Stage IV | 02/13 | 11/13 | | |
NCT00615784: Phase II Study of Bexarotene in Patients With Acute Myeloid Leukemia |
|
|
| Terminated | 2 | 24 | US | Bexarotene | Abramson Cancer Center of the University of Pennsylvania | Acute Myeloid Leukemia | 10/13 | 11/13 | | |
NCT00030589: Chemotherapy and Photodynamic Therapy in Treating Patients With Cutaneous T-Cell Lymphoma |
|
|
| Unknown status | 2 | | US | bexarotene, methoxsalen, UV light therapy | Millennix | Lymphoma | | | | |
NCT00125359: Study of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung Cancer |
|
|
| Completed | 2 | 42 | US | erlotinib and bexarotene | Konstantin Dragnev, Ligand Pharmaceuticals, Genentech, Inc. | Carcinoma, Non-small-cell Lung | 03/14 | 03/14 | | |
| Completed | 2 | 20 | US | Bexarotene, Targretin, Placebo | The Cleveland Clinic | Alzheimer's Disease | 08/14 | 12/14 | | |
2014-003145-99: A trial to determine bexarotene's safety and tolerability and it's ability to promote brain repair in patients with multiple sclerosis. |
|
|
| Ongoing | 2 | 50 | Europe | Bexarotene, Capsule, hard, Targretin | Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge | Relapsing-remitting multiple sclerosis already on interferon-beta therapy, Multiple Sclerosis, Diseases [C] - Nervous System Diseases [C10] | | | | |
NCT00425477: Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia |
|
|
| Completed | 2 | 26 | US | sargramostim, bexarotene, cytogenetic analysis, fluorescence in situ hybridization, flow cytometry, laboratory biomarker analysis, biopsy | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, National Cancer Institute (NCI) | Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases | 09/16 | 09/16 | | |
NCT00255801: Liposomal Doxorubicin Followed By Bexarotene in Treating Patients With Cutaneous T-Cell Lymphoma |
|
|
| Completed | 2 | 37 | US | Targretin® (bexarotene), pegylated liposomal doxorubicin hydrochloride | Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI), Tibotec Pharmaceutical Limited, M.D. Anderson Cancer Center, NYU Langone Health, Hackensack Meridian Health, Roswell Park Cancer Institute | Lymphoma | 10/17 | 10/17 | | |
NCT00411632: BATTLE Program: Tarceva and Targretin in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) |
|
|
| Completed | 2 | 37 | US | Bexarotene, Targretin, Erlotinib, Tarceva, OSI-774 | M.D. Anderson Cancer Center, United States Department of Defense | Lung Cancer | 02/18 | 02/18 | | |
NCT00306969: Study of Oral Bexarotene in Combination With Photopheresis for Treatment of Cutaneous T-Cell Lymphoma |
|
|
| Completed | 1/2 | 18 | US | bexarotene, photopheresis | Boston University, Ligand Pharmaceuticals | Cutaneous T-Cell Lymphoma | | 04/04 | | |
NCT00238628: A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung Cancer |
|
|
| Completed | 1/2 | 12 | US | Bexarotene, Iressa | Stanford University, Ligand Pharmaceuticals, AstraZeneca | Lung Cancer | 04/05 | 12/05 | | |
|
NCT00153842: A Study of Paclitaxel and Carboplatin in Combination With Bexarotene Oral Capsules in Patients With Advanced Lung Cancer |
|
|
| Terminated | 1/2 | 33 | US | Bexarotene (targretin), Targretin, LGD1069 | Dartmouth-Hitchcock Medical Center, Bristol-Myers Squibb, Ligand Pharmaceuticals | Carcinoma, Non-small-cell Lung | 03/09 | 03/09 | | |
NCT00845351: Preoperative Bexarotene Treatment for Cushing's Disease |
|
|
| Unknown status | 1/2 | 6 | US | Bexarotene | University of Virginia | Cushing's Disease | 12/11 | 12/11 | | |
